Efficacy of adjunctive cenobamate by focal seizure subtypes: a randomized, double-blind, placebo-controlled, multicenter study in a multinational Asian population
Open Access
- 30 September 2025
- journal article
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 133, 43-51
Abstract
No abstract availableKeywords
Funding Information
- SK Life Science Inc
This publication has 42 references indexed in Scilit:
- Switching carbamazepine to lacosamide improves gamma‐glutamyl transpeptidase levelsEpilepsia Open, 2024
- Dose Adjustment of Concomitant Antiseizure Medications During Cenobamate Treatment: Expert Opinion Consensus RecommendationsNeurology and Therapy, 2022
- The burden of epilepsy and unmet need in people with focal seizuresBrain and Behavior, 2022
- PERMIT study: a global pooled analysis study of the effectiveness and tolerability of perampanel in routine clinical practiceJournal of Neurology, 2021
- Positive allosteric modulation of GABAA receptors by a novel antiepileptic drug cenobamateEuropean Journal of Pharmacology, 2020
- Effects of cenobamate (YKP3089), a newly developed anti-epileptic drug, on voltage-gated sodium channels in rat hippocampal CA3 neuronsEuropean Journal of Pharmacology, 2019
- Understanding the burden of focal epilepsy as a function of seizure frequency in the United States, Europe, and BrazilEpilepsia Open, 2017
- Efficacy, safety, and tolerability of adjunctive brivaracetam for secondarily generalized tonic-clonic seizures: Pooled results from three Phase III studiesEpilepsy Research, 2016
- Response to placebo in clinical epilepsy trials—Old ideas and new insightsEpilepsy Research, 2016
- Efficacy of lacosamide by focal seizure subtypeEpilepsy Research, 2014